Amgen and AstraZeneca’s Tezspire (tezepelumab-ekko) gains FDA approval as an add-on maintenance therapy for patients aged 12 and older with inadequately controlled chronic rhinosinusitis with nasal ...
October 2025 Tezspire approved in the US for chronic rhinosinusitis with nasal polyps Approval broadens indication for Tezspire to a second disease characterised by epithelial-driven inflammationAstra ...
A new study has found that using indoor wood-burning stoves may damage lungs in a way similar to cigarette smoke.
Patients with IPF and emphysema who received antifibrotic agents had similar outcomes to patients with IPF alone.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果